Reflecting on the use of CDK4/6 inhibitors in HR+ breast cancer
Giuseppe Curigliano, MD, PhD, University of Milan, Milan, Italy, outlines future directions in the treatment and management of patients with…
Giuseppe Curigliano, MD, PhD, University of Milan, Milan, Italy, outlines future directions in the treatment and management of patients with…
Adam Januszewski, St Bartholomew’s Hospital in London, provides an overview of a session he chaired at the BTOG 2024 congress focusing on therapeutics, particularly exploring…
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the…
Georgina V. Long, PhD, MBBS, FRACP, FAHMS, The University of Sydney, North Sydney, Australia, discusses the Phase II SECOMBIT (NCT02631447) trial, which evaluated the best…
Enrique Grande, MD, PhD, MD Anderson Cancer Centre Madrid, Madrid, Spain, discusses the implications of the findings from the EV-302 trial (NCT04223856) of enfortumab vedotin,…
Aasma Shauka, MD, MPH, New York University, New York, NY, discusses the current landscape of colonoscopy screening in the United States. Colonoscopy is the primary…
Christoffer Gebhardt, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, summarizes the emerging immunotherapeutic treatment landscape for patients with melanoma. The ongoing Phase III INTerpath-001 trial…
Mariana Brandao, MD, PhD, Institute Jules Bordet, Brussels, Belgium, delves into the complexities of defining operability in non-small cell lung cancer (NSCLC), acknowledging the unique…
Charles Swanton, Francis Crick Institute in London, discusses his research on the initiation and progression of lung cancer in response to air pollution exposure. Focusing…
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the…
Natasha Leighl, MD, University of Toronto, Toronto, Canada, discusses findings from the Phase Ib CHRYSALIS trial (NCT02609776) of amivantamab, an EGFR-MET bispecific antibody, in patients…